多替阿巴拉米片是治什么的？

(Simeikai) is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a weight of at least 40 kg). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

For adults and adolescents, the recommended dose of Dolutebane is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. Dolutegravir, abacavir, or lamivudine is a fixed-dose tablet and should not be used in patients who require dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.

If the patient misses a dose of Doptabalamid Tablets (Suimeike), and there are more than 4 hours before the next dose, he should take Doptabalamid Tablets (Suimeike) as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

There are limited clinical safety data for (Suimax). The most commonly reported adverse reactions thought to be possibly or probably related to dolutegravir and abacavir/lamivudine (pooled data from 679 antiretroviral-naïve subjects who received this combination in phase IIb to IIIb clinical trials) were nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).